Fairfield Financial Advisors LTD Purchases New Shares in Charles River Laboratories International, Inc. (NYSE:CRL)

Fairfield Financial Advisors LTD acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 592 shares of the medical research company’s stock, valued at approximately $122,000.

A number of other institutional investors have also recently bought and sold shares of CRL. Czech National Bank increased its position in Charles River Laboratories International by 0.5% in the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock valued at $2,445,000 after acquiring an additional 41 shares during the period. Oregon Public Employees Retirement Fund grew its stake in shares of Charles River Laboratories International by 1.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after purchasing an additional 45 shares during the last quarter. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 57 shares during the period. Dumont & Blake Investment Advisors LLC raised its position in Charles River Laboratories International by 1.4% during the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock worth $1,196,000 after purchasing an additional 62 shares during the last quarter. Finally, Mitchell & Pahl Private Wealth LLC raised its position in Charles River Laboratories International by 2.0% during the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock worth $652,000 after purchasing an additional 62 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 2.2 %

CRL stock opened at $198.61 on Monday. The stock’s 50 day simple moving average is $209.40 and its 200 day simple moving average is $225.43. The company has a market cap of $10.23 billion, a P/E ratio of 23.37, a price-to-earnings-growth ratio of 3.89 and a beta of 1.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. On average, research analysts expect that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has initiated a share repurchase plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

CRL has been the subject of several recent research reports. TD Cowen decreased their price target on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Mizuho started coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target on the stock. StockNews.com upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Tuesday, August 20th. Finally, Evercore ISI dropped their target price on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Ten research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $231.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).